Literature DB >> 26921205

The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans.

Stefano Ballestri1, Fabio Nascimbeni2,3, Dante Romagnoli2, Enrica Baldelli3, Amedeo Lonardo4.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) describes steatosis, nonalcoholic steatohepatitis with or without fibrosis, and hepatocellular carcinoma, namely the entire alcohol-like spectrum of liver disease though observed in the nonalcoholic, dysmetabolic, individual free of competing causes of liver disease. NAFLD, which is a major public health issue, exhibits intrahepatic triglyceride storage giving rise to lipotoxicity. Nuclear receptors (NRs) are transcriptional factors which, activated by ligands, are master regulators of metabolism and also have intricate connections with circadian control accounting for cyclical patterns in the metabolic fate of nutrients. Several transcription factors, such as peroxisome proliferator-activated receptors, liver X receptors, farnesoid X receptors, and their molecular cascades, finely regulate energetic fluxes and metabolic pathways. Dysregulation of such pathways is heavily implicated in those metabolic derangements characterizing insulin resistance and metabolic syndrome and in the histogenesis of progressive NAFLD forms. We review the role of selected NRs in NAFLD pathogenesis. Secondly, we analyze the role of NRs in the natural history of human NAFLD. Next, we discuss the results observed in humans following administration of drug agonists or antagonists of the NRs pathogenically involved in NAFLD. Finally, general principles of treatment and lines of research in human NAFLD are briefly examined.

Entities:  

Keywords:  Cirrhosis; Farnesoid X receptor; Fibrosis; Hepatocellular carcinoma; Liver X receptor; Natural history; Nonalcoholic steatohepatitis; Pathogenesis; Peroxisome proliferator-activated receptor; Steatosis

Mesh:

Substances:

Year:  2016        PMID: 26921205     DOI: 10.1007/s12325-016-0306-9

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  25 in total

Review 1.  Endocrine-disrupting chemicals and fatty liver disease.

Authors:  Charles E Foulds; Lindsey S Treviño; Brian York; Cheryl L Walker
Journal:  Nat Rev Endocrinol       Date:  2017-05-19       Impact factor: 43.330

Review 2.  The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View.

Authors:  Christina C Lindenmeyer; Arthur J McCullough
Journal:  Clin Liver Dis       Date:  2018-02       Impact factor: 6.126

Review 3.  Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review.

Authors:  Getnet Teshome; Sintayehu Ambachew; Alebachew Fasil; Molla Abebe
Journal:  Hepat Med       Date:  2020-09-24

Review 4.  Nuclear receptors in the kidney during health and disease.

Authors:  Andrew E Libby; Bryce Jones; Isabel Lopez-Santiago; Emma Rowland; Moshe Levi
Journal:  Mol Aspects Med       Date:  2020-11-30

Review 5.  Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight.

Authors:  Stefano Ballestri; Fabio Nascimbeni; Dante Romagnoli; Enrica Baldelli; Giovanni Targher; Amedeo Lonardo
Journal:  Int J Mol Sci       Date:  2016-03-09       Impact factor: 5.923

Review 6.  Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV.

Authors:  Amedeo Lonardo; Stefano Ballestri; Giovanni Guaraldi; Fabio Nascimbeni; Dante Romagnoli; Stefano Zona; Giovanni Targher
Journal:  World J Gastroenterol       Date:  2016-11-28       Impact factor: 5.742

7.  A Combination of Leucine, Metformin, and Sildenafil Treats Nonalcoholic Fatty Liver Disease and Steatohepatitis in Mice.

Authors:  Antje Bruckbauer; Jheelam Banerjee; Lizhi Fu; Fenfen Li; Qiang Cao; Xin Cui; Rui Wu; Hang Shi; Bingzhong Xue; Michael B Zemel
Journal:  Int J Hepatol       Date:  2016-11-30

8.  Biochemical mechanism underlying hypertriglyceridemia and hepatic steatosis/hepatomegaly induced by acute schisandrin B treatment in mice.

Authors:  Yi Zhang; Jing Zhao; Shu-Feng Zhou; Zhi-Ling Yu; Xiao-Yan Wang; Pei-Li Zhu; Zhu-Sheng Chu; Si-Yuan Pan; Ming Xie; Kam-Ming Ko
Journal:  Lipids Health Dis       Date:  2017-01-13       Impact factor: 3.876

Review 9.  Generic chemoprevention of hepatocellular carcinoma.

Authors:  Sai Krishna Athuluri-Divakar; Yujin Hoshida
Journal:  Ann N Y Acad Sci       Date:  2018-09-17       Impact factor: 6.499

10.  PNPLA3 Expression Is Related to Liver Steatosis in Morbidly Obese Women with Non-Alcoholic Fatty Liver Disease.

Authors:  Gemma Aragonès; Teresa Auguet; Sandra Armengol; Alba Berlanga; Esther Guiu-Jurado; Carmen Aguilar; Salomé Martínez; Fátima Sabench; José Antonio Porras; Maikel Daniel Ruiz; Mercé Hernández; Joan Josep Sirvent; Daniel Del Castillo; Cristóbal Richart
Journal:  Int J Mol Sci       Date:  2016-04-27       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.